Cargando…
P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431522/ http://dx.doi.org/10.1097/01.HS9.0000971144.30344.9c |
| _version_ | 1785091222201696256 |
|---|---|
| author | Palandri, Francesca Masarova, Lucia Verstovsek, Srdan Mesa, Ruben Harrison, Claire Sajeev, Gautam Gorsh, Boris Simpson, Ryan Cho, Sang Wang, Zhaohui Ellis, Catherine Conlon, Sean Signorovitch, James |
| author_facet | Palandri, Francesca Masarova, Lucia Verstovsek, Srdan Mesa, Ruben Harrison, Claire Sajeev, Gautam Gorsh, Boris Simpson, Ryan Cho, Sang Wang, Zhaohui Ellis, Catherine Conlon, Sean Signorovitch, James |
| author_sort | Palandri, Francesca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431522 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104315222023-08-17 P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS Palandri, Francesca Masarova, Lucia Verstovsek, Srdan Mesa, Ruben Harrison, Claire Sajeev, Gautam Gorsh, Boris Simpson, Ryan Cho, Sang Wang, Zhaohui Ellis, Catherine Conlon, Sean Signorovitch, James Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431522/ http://dx.doi.org/10.1097/01.HS9.0000971144.30344.9c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Palandri, Francesca Masarova, Lucia Verstovsek, Srdan Mesa, Ruben Harrison, Claire Sajeev, Gautam Gorsh, Boris Simpson, Ryan Cho, Sang Wang, Zhaohui Ellis, Catherine Conlon, Sean Signorovitch, James P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_full | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_fullStr | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_full_unstemmed | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_short | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_sort | p1062: indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431522/ http://dx.doi.org/10.1097/01.HS9.0000971144.30344.9c |
| work_keys_str_mv | AT palandrifrancesca p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT masarovalucia p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT verstovseksrdan p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT mesaruben p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT harrisonclaire p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT sajeevgautam p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT gorshboris p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT simpsonryan p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT chosang p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT wangzhaohui p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT elliscatherine p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT conlonsean p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT signorovitchjames p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis |